COMS for Chronic Ulcers Treatment (NAZARÉ)

NAZARÉ: Concurrent Optical and Magnetic Stimulation (COMS) for Treatment of Patients With Chronic Ulcers of Vascular Origin in a Real-world Setting Including Care at Patient's Home, a Prospective Randomized, Controlled, Assessor Blinded, Phase IV, Clinical Trial

Chronic leg and foot ulcers are defined as wounds that fail to heal in a timely manner, typically persisting for over 4 to 8 weeks without substantial healing despite standard care. These ulcers often result from macro- and microvascular disorders, the most common being chronic venous insufficiency (CVI), alone or with peripheral artery disease (PAD) or microangiopathy. Despite different causes, chronic vascular-origin wounds share similar biological traits and require the same physiological processes for healing.

Vascular issues hinder blood perfusion, reducing oxygen, nutrients, and growth factors, leading to decreased energy metabolism and impaired cell functions necessary for proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Reduced blood supply also limits leukocyte function, compromising the immune response and leading to persistent inflammation and infection. Consequently, these wounds cannot effectively heal, showing prolonged inflammation, persistent infections, and cellular senescence.

Best practice wound care includes compression therapy and physical activity for venous ulcers, and angioplasty, surgery, or bypass for arterial ulcers. These treatments aim to improve blood flow, reduce venous stasis, and enhance venous return. Compression therapy and physical activity lower hydrostatic pressure in the lower limb, while angioplasty and surgery remove arterial blockages or create new blood flow routes.

Recent studies highlight the role of mechano-sensitive (MS) ion channels in skin cell processes and their dysfunction in dermatological disorders. Magnetic stimulation can activate MS TRCP1 channels, enhancing mitochondrial respiration and mitochondriogenesis via the Ca2+/CalModulin(CaM)/NFAT/PGC-1α pathway. Ca2+-activated calmodulin also catalyzes nitric oxide (NO), promoting vasodilation and tissue perfusion.

Bimodal red and near-infrared photobiomodulation can further increase mitochondrial respiration and ATP production by activating Cytochrome C oxidase and mitigating NO-induced downregulation. This synergistic mechanism of concurrent optical and magnetic stimulation (COMS) may amplify Ca2+ and NO-mediated processes like cell proliferation, migration, vasodilation, and angiogenesis while resolving inflammation. Thus, COMS may offer a promising therapy for chronic, inflammation-prone wounds.

The effectiveness of COMS has yet to be validated in large-scale studies. This proposal aims to assess the impact of COMS therapy combined with standard care versus standard care alone on healing, wound closure, recurrence, pain, quality of life, economic outcomes, and device usability in patients with venous leg ulcers (VLU) and VLU associated with PAD in a large-scale multicentric randomized controlled trial.

Study Overview

• Status: Recruiting
• Conditions: Wound Heal; Venous Leg Ulcer; Magnetic Field Exposure
• Intervention / Treatment: Combination product: Concurrent optical and magnetic stimulation (COMS) treatment

Detailed Description

Background: Chronic leg and foot ulcers are defined as wounds which fail to proceed through phases of wound healing in an orderly and timely manner to produce a durable structural functional and cosmetic closure. Depending on care setting / geographical region, wounds are considered chronic if they persist over more than 4 to 8 weeks with no substantial wound healing under standard of care (SOC) treatment regimen.

Among the most frequent causes for a delayed wound healing process are macro- and microvascular disorders. The most common is a chronic venous insufficiency (CVI), either as standalone or in combination with peripheral artery disease (PAD) or microangiopathy. Despite their differences in etiology, chronic wounds of vascular origin share similar biological features and require promotion of the same physiological processes for wound healing. The vascular constraints reduce blood perfusion and hinder appropriate cellular supply with oxygen, nutrients, and growth factors. This leads to decreased energy metabolism and therefore impaired cellular performance required for cell proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Additionally, reduced vascular supply decreases the number and ability of leukocytes to engage oxidative bursts, limiting the capacity for efficient pathogen destruction and leading to tissue devitalization. Consequently, the immune response becomes insufficient to deal with the local pathogen load, leading to ongoing inflammation in the wound area. In summary chronic wounds of vascular origins are unable to run through processes of wound healing, showing an inability to respond to local reparative stimuli of the wound environment, prolonged inflammation, persistent infections, and cellular senescence.

Best practice wound care emphasizes the utilization of compression therapy and physical activity for leg ulcers of venous etiology and angioplasty, surgery, or bypass operation for leg ulcers of arterial etiology, both axes of care being guided by the integration of healthcare professionals' clinical expertise with the best available clinical evidence. Compression therapy and physical activity facilitate wound healing by reducing hydrostatic pressure in the lower limb, mitigating venous stasis, and enhancing venous return. To improve the blood supply to the ulcer, angioplasty and surgery aims to clear out a blockage from a leg artery (endarterectomy), while bypass operation aims to put in a new route for blood flow in the leg.

Concurrent Optical and Magnetic Stimulation Recent publications have demonstrated the importance of mechano-sensitive (MS) ion channels in regulating processes such as skin cell proliferation, differentiation and barrier formation and linked their dysfunction to dermatological disorders. Magnetic stimulation has been shown to activate mechanosensitive TRCP1 channels, whereby the resulting ion channel-mediated calcium fluxes stimulate mitochondrial respiration and associated mitochondriogenesis through activation of the Ca2+/CalModulin(CaM) /NFAT/PGC-1α pathway. Ca2+-activated calmodulin has also been shown lead to the catalyzation of nitric oxide (NO), a potent mediator for vasodilation and tissue perfusion.

The concurrent bimodal red and near-infrared photo biomodulation, can further increase mitochondrial respiration and intracellular ATP production through activation of the Cytochrome C oxidase and mitigating its downregulation by increased levels of intracellular NO through its photo dissociation. Through this synergistic mechanism COMS may offer a therapeutic option for amplifying Ca2+ and NO mediated processes such as cell proliferation, migration, vasodilation, and angiogenesis while helping to shift the cytokine profile towards resolution of inflammation. Therefore, COMS may offer a promising therapeutic approach to enable the transition toward healing of therapy refractory wounds that tend to stay in inflammatory phase. The effectiveness of COMS has not yet been tested in a large-scale study. We propose here to assess the impact of COMS therapy+SOC versus SOC only, on healing, wound closure, wound recurrence, pain, quality of life, economic outcomes and device usability, in patients with venous leg ulcers (VLU) and VLU associated with PAD, in a large-scale multicentric randomized controlled trial.

Design: This study is a post market, phase IV clinical trial. A multicentric randomized controlled trial design will be used. 122 consecutive eligible patients with VLU or VLU associated with PAD, cared in outpatient or home settings in Switzerland (6 sites), France (1 site), Germany (2 sites) and Austria (2 sites), will be included and randomly allocated to one of the two study groups. Half of the participants will receive the standard of care (control group) and the other half will receive the standard of care, supplemented with COMS treatment during the 8 first week's post-inclusion (intervention group). Total study duration for each participant will be 24 weeks.

The intervention is single-blinded, i.e. it not blinded to participants and health care professionals but blinded to data assessors. Analysis:

The entire sample (intervention and control groups) will be described, according to the data level, in terms of their demographic and health data, using descriptive statistics. For the analysis of the different outcomes, the proportions or mean values will be compared between control and intervention groups by using classical tests of hypotheses. Additional analyses will be conducted to assess the change of the wound size over time and to compare groups. The statistical software for data science STATA 17.0 SAS version 9.4 or later (SAS Institute Inc., Cary, NC) will be used for data analysis.

• Study Type: Interventional
• Enrollment (Estimated): 122
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Sebastian Probst, Prof. Dr.; Phone Number: 122-558-6563; Email: sebastian.probst@hesge.ch
• Study Contact Backup: Name: Camille Saini, Dr.; Phone Number: 122-558-5274; Email: camille.saini@hesge.ch

Study Locations

• Austria
  • Graz, Austria
    • Not yet recruiting
    • Medizinische Universität Graz
    • Contact: Lars-Peter Kamolz, Prof.; Phone Number: +43 316 385-14685; Email: lars.kamolz@medunigraz.at
  • Vienna, Austria
    • Not yet recruiting
    • Medizinische Universitat Wien
    • Contact: Benedikt Weber, Prof.; Phone Number: +43 1 40400-77500; Email: benedikt.weber@meduniwien.ac.at
• France
  • Malestroit, France
    • Not yet recruiting
    • Augustines's Clinic
    • Contact: Jean-Paul Lembelembe, Dr.; Phone Number: +33 02 97 73 18 24; Email: jplembelembe@ghsa.fr
• Germany
  • Essen, Germany
    • Not yet recruiting
    • Universitätsklinikum Essen
    • Contact: Joachim Dissemond, Prof.; Phone Number: +49 0201 723 36 41; Email: Joachim.Dissemond@uk-essen.de
  • Hamburg, Germany
    • Not yet recruiting
    • University Clinic Hamburg-Eppendorf
    • Contact: Ewa Stürmer, Prof.; Phone Number: +49 0201 723 36 41; Email: Joachim.Dissemond@uk-essen.de
• Switzerland
  • Delémont, Switzerland
    • Not yet recruiting
    • Jura Hospital
    • Contact: Claudio Ruzza, Dr.; Phone Number: +41 32 421 27 93; Email: Claudio.Ruzza@h-ju.ch
  • Kreuzlingen, Switzerland
    • Recruiting
    • Venenklinik Bellevue
    • Contact: Jürg Traber, Dr.; Phone Number: +41 71 678 22 66; Email: j.traber@venenklinik.ch
  • Onex, Switzerland
    • Not yet recruiting
    • Cité Générations
    • Contact: Dave Baer, Dr.; Phone Number: +4122 709 00 00; Email: dave.baer@cpo.ch
  • Thun, Switzerland
    • Not yet recruiting
    • Spital Thun
    • Contact: Thomas Zehnder, Dr.; Phone Number: +41 58 636 27 44; Email: Thomas.Zehnder@spitalstsag.ch
  • Zurich, Switzerland
    • Not yet recruiting
    • University Hospital
    • Contact: Jürg Hafner, Prof.; Phone Number: +41 44 255 44 87; Email: Juerg.hafner@usz.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Age ≥ 18 years Clinical diagnosis of venous leg ulcer (VLU) or VLU with peripheral arterial disease (PAD) Ankle-brachial index (ABI) 0.5-1.3 or ankle pressure > 60 mmHg Ulcer size 2-50 cm² after debridement at screening Ulcer duration > 30 days and < 2 years For patients with diabetes: HbA1c ≤ 12% at screening Able and willing to provide written informed consent prior to study procedures

Exclusion Criteria:

Pregnant or breastfeeding Malignancy in the ulcer area Use of photosensitizing medication within 30 days Severe immunosuppression (including chronic corticosteroid use > 10 mg/day prednisolone equivalent) NYHA class III or IV heart failure End-stage renal disease requiring dialysis Ulcer area reduction > 30% during run-in phase Active infection requiring systemic antibiotics at baseline Use of advanced wound therapies (e.g., negative pressure wound therapy, skin substitutes, hyperbaric oxygen) within 2 weeks prior to screening Participation in another interventional clinical trial within 30 days

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Device Feasibility
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: usual care; Standard of Care treatment will be performed according to a provided standard of care manual according to most recent guidelines followed at each corresponding site (EWMA , S3-Leitlinie,…) and will proceed as follows: Removal of old dressing; Application of analgesic if necessary; Debridement if necessary; Wound cleansing; Application of new dressing (according to the wound healing phases, medical prescription); Application of compression therapy according to study standardized procedure (details in section 6.1). In the case the participant is at home, this procedure will be performed by a caregiver.
Experimental: COMS Therapy; COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps: Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1) If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device.	Combination product: Concurrent optical and magnetic stimulation (COMS) treatment; COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps: Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1) If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent wound area reduction	Percent wound area reduction (PWAR) at week 12 will be measured from pictures of the wound taken with ImitoWound research application. PWAR is computed as (Wound area at baseline - Wound area at 12 weeks) / Wound area at baseline. The picture of the wound will be taken after dressing removal, wound debridement (if applicable) and wound cleansing. ImitoWound research App will be used in an iPad as instructed in supplier's wound imaging and measurement guidelines. The camera of the iPad will be positioned 20 to 30 cm away from and parallel to the wound. A calibration marker (quick response [QR] code) will be positioned next to and in the same plane of the wound, and a photograph will be taken after recognition of the QR code by the Imito App, automatic wound measurement will take place. Study nurses will receive concise training and a working instruction with step-by-step procedure on how to use Imito App. (See Appendices) Each wound contour will then be checked and confirmed by an expe	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete wound closure	1) Complete wound closure after 8, 12, 16, 20, 24 weeks. Complete wound closure is defined as complete skin re-epithelialization without drainage confirmed by 2 consecutive trial visits 2 weeks apart	24 weeks
Percent Wound Area Reduction (PWAR	Percent Wound Area Reduction (PWAR) at week 4, 8, 16, 20, 24 will be measured from pictures of the wound taken with ImitoWound	24 weeks
Change in Pain assessment	Change in Pain assessment at week 12 vs. week 0 (VAS Scale). Patient's perception in terms of pain will be assessed using Visual Analog Scale (VAS) from 0 (no pain) to 10 (very strong pain). It will be asked the participant to use this scale to give a measure of general pain perceived prior to any treatment. The use of VAS offers a widespread potential to document the characteristics of disease-related symptoms (Gethin et al. 2014). Such scales are successfully used in the assessment of wound-related symptoms, are inexpensive and easily understood.	24 weeks
Median time-to-healing	Median time-to-healing (50, 90, 100%) through up to week 24	24 weeks
Ulcer re-occurrence rate	Ulcer re-occurrence rate through up to week 24. Recurrence is when a VLU reopens in the same location after healing.	24 weeks
Change in Wound-QoL	4) Change in Wound-QoL questionnaire at week 12 vs. week 0 (Wound-QoL). Wound-QoL is a short and easy-to-understand instrument to assess health related quality of life in patients with chronic wounds, especially leg ulcers. It consists of one page 17 Likert scaled items assessing impairments within the preceding seven days. Answers to each item are coded with numbers (0='not at all' to 4='very much'). A Wound-QoL-17 global score on overall disease-specific quality of life is computed by averaging all items. In addition, subscales of the Wound-QoL can be calculated representing different dimensions of disease-specific quality of life by averaging the respective items ("Body": items 1-5, "Psyche": items 6-10 and "Everyday life": items 11-16). Validated translations have been performed in French (France and Switzerland) and German (Germany, Austria and Switzerland).	24 weeks

Collaborators and Investigators

• Sponsor: Sebastian Probst
• Collaborators: Medical University of Graz; Medical University of Vienna; University Hospital, Geneva; University Hospital, Zürich; Universität Duisburg-Essen; University of Hamburg-Eppendorf; Venenklinik Bellevue; Medical Centre Cité Générations; Jura Hospital; Clinique des Augustines; Hospital Thun

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2025
• Primary Completion (Estimated): August 31, 2026
• Study Completion (Estimated): September 30, 2026

Study Registration Dates

• First Submitted: July 26, 2024
• First Submitted That Met QC Criteria: July 26, 2024
• First Posted (Actual): July 30, 2024

Study Record Updates

• Last Update Posted (Actual): May 8, 2026
• Last Update Submitted That Met QC Criteria: May 4, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Venous leg ulcer; magnetic stimulation; optical stimulation
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Skin Diseases; Skin Ulcer; Varicose Veins; Leg Ulcer; Skin and Connective Tissue Diseases; Varicose Ulcer; Therapeutics
• Other Study ID Numbers: NAZARÉ; PIOMIC (Other Identifier: PIOMIC)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Raw data will be shared using Yareta (https://yareta.unige.ch/home) a Swiss research platform using the FAIR priniples
• IPD Sharing Time Frame: from 2027 until 2029
• IPD Sharing Access Criteria: all researchers
• IPD Sharing Supporting Information Type: ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No